Anti-CYP2D6 Antibody

For laboratories investigating CYP2D6-mediated hepatic drug metabolism, this polyclonal antibody from Antibodies.com targets the cytochrome P450 2D6 enzyme, a microsomal monooxygenase responsible for oxidizing a substantial fraction of clinically prescribed drugs, including many antidepressants, beta-blockers, and opioid analgesics. Raised in rabbit and supplied as an IgG preparation, the reagent is delivered unconjugated in a 100 µl volume, allowing direct incorporation into standard western blot and immunohistochemistry protocols without an intermediate labeling step.

Cross-reactivity has been validated against human, mouse, and rat samples, making the antibody useful for translational studies that compare CYP2D6 expression across species, including pharmacogenomic investigations of poor, intermediate, extensive, and ultrarapid metabolizer phenotypes. In western blot, the antibody detects the full-length enzyme from liver-derived lysates; in IHC, it produces cytoplasmic staining consistent with the endoplasmic reticulum localization of microsomal P450 proteins. Investigators studying drug-drug interactions, hepatic toxicology, or personalized-medicine cohorts can pair this reagent with secondary antibodies for chromogenic or chemiluminescent readout.

For handling, keep the vial refrigerated and aliquot before freezing for longer-term storage to limit freeze-thaw cycles; avoid sodium azide if downstream HRP conjugation is planned. The unconjugated format leaves users free to choose fluorophore or enzyme conjugates, which is particularly valuable when multiplexing CYP2D6 with other P450 family members such as CYP3A4 or CYP2C19 on the same tissue section.